摘要
目的：观察氟哌噻吨美利曲辛治疗脑卒中后抑郁症和（或）焦虑症的临床效果。方法：选取2011年10月—2014年10月120例脑卒中后有抑郁症和（或）焦虑症的患者，以随机数字表法分为治疗组和对照组各60例。在常规治疗的基础上，治疗组患者给予氟哌噻吨美利曲辛片1日2～4片，对照组给予阿米替林1次1～2片、1日3次，疗程8周。采用汉密尔顿抑郁量表（ HAMD）、汉密尔顿焦虑量表（ HAMA）、临床疗效总评量表（ CGI）、治疗副反应量表（ TESS）评价2种药物的临床疗效和不良反应，采用生活质量综合评定问卷（ GQOLI）评价患者的生活质量。结果：治疗8周后，治疗组患者HAMD、HAMA总分均较治疗前显著下降（P＜0.01），不良反应较对照组少（P＜0.01），CGI、GQOLI评分有所提高。结论：应用氟哌噻吨美利曲辛治疗脑卒中后抑郁和（或）焦虑症，疗效确切，且使用方便，毒副作用小。
OBJECTIVE：To evaluate the clinical efficacy of Flupentixol Melitracen tablets for post-stroke depression and（ or） anxiety disorder.METHODS： Between Oct.2011 and Oct.2014, a total of 120 patients with post-stroke depression and（ or） anxiety disorders were randomized to either treatment group or control group of 60 cases each.The treatment group received add-on Flupentixol Melitracen tablets（2-4 tablets daily） while the control group received amitriptyline （1-2 tablets/time multiply three times daily） for 8 weeks.Hamilton Depression Rating Scale （ HAMD ） , Hamilton Anxiety Scale （ HAMA ） , Clinical Global Impression Scale （ CGI ） and Treatment Emergent Sympton Scale （ TESS） were employed for evaluation of the efficacy and adverse drug reactions of two drugs;General Quality Of Life Inventory （ GQOLI） was used for evaluation of the quality of life of patients.RESULTS：After 8-week treatment, the total score in HAMD and HAMA in the treaetment group were significantly lower than before treatment （ P〈0.01 ） and the adverse reactions were less in the treaetment group than in the control group （ P〈0.01 ） , CGI score and GQOLI score increased than before treatment.CONCLUSIONS：Flupentixol Melitracen is safe and effective and convinent to use in treatment of post-stroke depression and （ or） anxiety disorder.
出处
《中国医院用药评价与分析》
2015年第5期590-592,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
